Revista de Gastroenterología del Perú
ISSN 1022-5129 versión impresa
MARCOS, Luis, TERASHIMA, Angélica, SAMALVIDES, Frine et al. Tiabendazol para el control de la infección por Strongyloides stercoralis en una zona hiperendémica en el Perú. Rev. gastroenterol. Perú, oct./dic. 2005, vol.25, no.4, p.341-348. ISSN 1022-5129.
Strongyloides stercoralis infection is a disease caused by an intestinal parasite. This helminth is highly prevalent in tropical and subtropical areas. The preferred treatment is ivermectin, and tiabendazole as a second option available in certain Peruvian institutions. The purpose of the study was to assess the efficacy and tolerability of tiabendazole (25 mg/kg/day) administered twice a day (after meals) for three days in individuals with S. stercoralis chronic infection. The study was conducted at Hospital de La Merced, Province of Chanchamayo, Peru (endemic area), during a 90 day period. The study included 32 individuals (22 female and 10 male, average age ± SD = 9.31 ± 8.11 years) with a diagnosed S. stercoralis infection. Follow up tests were eosinophil count, hematocrit, agar plate feces culture, and Baermann technique modified by Lumbreras. Healing rate was 90.6%. The average eosinophil count in healed patients significantly decreased (1168 to 665 eosinophils/cc, p=0.006) as compared to the treatment failure group, which showed a slight increase (618 to 897 eosinophils/cc, p=0.125). Hematocrit increased in both groups (2% and 3%, respectively). Adverse effects were headache, dizziness, and epigastralgia in 6.2% of individuals. It was concluded that the studied scheme showed a high effectiveness rate and was well tolerated. Therefore this scheme may be taken into account for control programs of this parasite in hyperendemic areas.
Palabras llave: Strongyloides stercoralis; tiabendazole; treatment; endemic areas; Peru.
Sociedad de Gastroenterología del Perú
Juan Aliaga Nº 204
Lima 17 - Perú
Telf.: 515-264 0015
Fax: 515-264 1400